Pharmaceutical Technology6d
QTX-3046 by Quanta Therapeutics for Colorectal Cancer: Likelihood of Approval
QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 7 ...
Pharmaceutical Technology6d
QTX-3046 by Quanta Therapeutics for Lung Cancer: Likelihood of Approval
QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase tra ...
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...
Business Wire4d
Acellera Therapeutics Unveils AceForce 1.0: A Novel Family of Next-Generation Neural Network Potential Accelerating Drug Discovery
Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of ...
SchaeffersResearch.com1d
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy
Keep an eye on the first patient dosed in phase 1 and 2 trials of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD),with ...
Joplin Globe5d
Acellera Therapeutics Unveils AceForce 1.0: A Novel Family of Next-Generation Neural Network Potential Accelerating Drug Discovery
Acellera Therapeutics, a pioneer in computational ... model designed to deliver quantum-level accuracy for predicting atomic interactions—an essential factor in identifying promising drug ...
Pharmabiz1d
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...
From Generative AI and ML to Quantum Computing, Bio-IT World 2025 Showcases Technologies Poised to Accelerate Lifesaving Therapies
Bio-IT World Conference & Expo, the premier annual gathering of 3,000 innovators at the intersection of IT and life sciences, ...